Literature DB >> 3081375

Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression.

R Fleming, J R Coutts.   

Abstract

Patients with normal menstrual rhythm and normal luteinizing hormone were treated with exogenous gonadotropins to induce multiple follicular development. This was effected in the absence (34 cycles in 12 patients) or with concurrent suppression of endogenous gonadotropin levels with a gonadotropin-releasing hormone analog (84 cycles in 18 patients). In the absence of the analog, "premature" luteinization occurred in 51% of cycles before the ultrasonic visualization of a follicle with a diameter of 20 mm. In the analog-treated cycles, premature luteinization was almost totally eliminated and progesterone elevations were delayed until after administration of human chorionic gonadotropin. Follicular estrogen production was unaffected by the analog treatment, compared with hypogonadal patients treated with exogenous gonadotropins. The characteristics of follicular development showed that two to three follicles of mature size were induced with this technique, and the capacity for the induction of a larger number of follicles was evident.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081375     DOI: 10.1016/s0015-0282(16)49159-4

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  26 in total

1.  Comparison between two hCG-to-oocyte aspiration intervals on the outcome of in vitro fertilization.

Authors:  S Bjercke; T Tanbo; P O Dale; T Abyholm
Journal:  J Assist Reprod Genet       Date:  2000-07       Impact factor: 3.412

2.  Improved pregnancy outcome with gonadotropin releasing hormone agonist (GnRH-a) stimulation is due to the improvement in oocyte quantity rather than quality.

Authors:  H C Liu; Y M Lai; O Davis; A S Berkeley; M Graf; J Grifo; J Cohen; Z Rosenwaks
Journal:  J Assist Reprod Genet       Date:  1992-08       Impact factor: 3.412

Review 3.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

4.  In vitro fertilization programmed for weekday-only oocyte harvest: analysis of outcome based on actual retrieval day.

Authors:  A Ben-Chetrit; S Senoz; E M Greenblatt
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

5.  Use of GnRH analogues in ovulation induction for in vitro fertilization: benefit of a short administration regimen.

Authors:  P Barriere; P Lopes; J P Boiffard; C Pousset; M Quentin; P Sagot; A L'Hermite; M F Lerat; B Charbonnel
Journal:  J In Vitro Fert Embryo Transf       Date:  1987-02

Review 6.  Clinical applications of GnRH analogs.

Authors:  G Forti
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

Review 7.  Drugs used in in vitro fertilisation procedures.

Authors:  I E Messinis
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

8.  Pituitary down-regulation using leuprolide for the intensive ovulation management of poor prognosis patients having in vitro fertilization (IVF)-related treatments.

Authors:  J M Cummins; J M Yovich; W R Edirisinghe; J L Yovich
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-12

Review 9.  Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.

Authors:  Luiz Eduardo T Albuquerque; Leopoldo O Tso; Humberto Saconato; Maria Cecília R M Albuquerque; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

10.  A controlled ovarian hyperstimulation regimen involving intermittent gonadotropin administration with a "short" protocol of gonadotropin releasing hormone agonist for in vitro fertilization.

Authors:  N Suganuma; S I Tsukahara; T Kitagawa; M Furuhashi; Y Asada; I Kondo
Journal:  J Assist Reprod Genet       Date:  1996-01       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.